Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) with a Buy recommendation. Analyst Price Forecast Suggests 14.22% ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders acquired 4,599 call options on the company. This represents an increase of ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

Tidal Investments LLC lessened its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 39.5% in the third quarter, according ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...